☰

Jeffrey J. Sutherland, Ph.D. - Publications

Affiliations: 
2004 Queen's University, Canada, Kingston, Ontario, Canada 
Area:
Pharmaceutical Chemistry
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Copple IM, den Hollander W, Callegaro G, Mutter FE, Maggs JL, Schofield AL, Rainbow L, Fang Y, Sutherland JJ, Ellis EC, Ingelman-Sundberg M, Fenwick SW, Goldring CE, van de Water B, Stevens JL, et al. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Archives of Toxicology. PMID 30426165 DOI: 10.1007/S00204-018-2354-1  0.329
2015 Lee JA, Shinn P, Jaken S, Oliver S, Willard FS, Heidler S, Peery RB, Oler J, Chu S, Southall N, Dexheimer TS, Smallwood J, Huang R, Guha R, Jadhav A, ... ... Sutherland JJ, et al. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. Plos One. 10: e0130796. PMID 26177200 DOI: 10.1371/Journal.Pone.0130796  0.302
2013 Sutherland JJ, Gao C, Cahya S, Vieth M. What general conclusions can we draw from kinase profiling data sets? Biochimica Et Biophysica Acta. 1834: 1425-33. PMID 23333421 DOI: 10.1016/J.Bbapap.2012.12.023  0.305
2012 Sutherland JJ, Raymond JW, Stevens JL, Baker TK, Watson DE. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. Journal of Medicinal Chemistry. 55: 6455-66. PMID 22716080 DOI: 10.1021/Jm300684U  0.303
2008 Nandigam RK, Evans DA, Erickson JA, Kim S, Sutherland JJ. Predicting the accuracy of ligand overlay methods with Random Forest models. Journal of Chemical Information and Modeling. 48: 2386-94. PMID 19053524 DOI: 10.1021/Ci800216F  0.357
2008 Sutherland JJ, Higgs RE, Watson I, Vieth M. Chemical fragments as foundations for understanding target space and activity prediction. Journal of Medicinal Chemistry. 51: 2689-700. PMID 18386916 DOI: 10.1021/Jm701399F  0.326
2007 Sutherland JJ, Nandigam RK, Erickson JA, Vieth M. Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy. Journal of Chemical Information and Modeling. 47: 2293-302. PMID 17956084 DOI: 10.1021/Ci700253H  0.34
2005 O'Brien LA, Sutherland JJ, Weaver DF, Lillicrap D. Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. Journal of Thrombosis and Haemostasis : Jth. 3: 796-7. PMID 15842374 DOI: 10.1111/J.1538-7836.2005.01219.X  0.459
2004 Sutherland JJ, Weaver DF. Three-dimensional quantitative structure-activity and structure-selectivity relationships of dihydrofolate reductase inhibitors. Journal of Computer-Aided Molecular Design. 18: 309-31. PMID 15595459 DOI: 10.1023/B:Jcam.0000047814.85293.Da  0.533
2004 Sutherland JJ, O'Brien LA, Weaver DF. A comparison of methods for modeling quantitative structure-activity relationships. Journal of Medicinal Chemistry. 47: 5541-54. PMID 15481990 DOI: 10.1021/Jm0497141  0.52
2004 Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. Journal of Molecular Modeling. 10: 259-70. PMID 15322948 DOI: 10.1007/S00894-004-0194-9  0.501
2004 Sutherland JJ, O'Brien LA, Weaver DF. Pruned receptor surface models and pharmacophores for three-dimensional database searching. Journal of Medicinal Chemistry. 47: 3777-87. PMID 15239656 DOI: 10.1021/Jm049896Z  0.511
2004 O'Brien LA, Sutherland JJ, Hegadorn C, Benford K, Racz H, Rapson D, Hough C, Lillicrap D. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. Journal of Thrombosis and Haemostasis : Jth. 2: 1135-42. PMID 15219197 DOI: 10.1111/J.1538-7836.2004.00732.X  0.331
2003 Sutherland JJ, O'Brien LA, Weaver DF. Spline-fitting with a genetic algorithm: a method for developing classification structure-activity relationships. Journal of Chemical Information and Computer Sciences. 43: 1906-15. PMID 14632439 DOI: 10.1021/Ci034143R  0.504
2003 Sutherland JJ, Weaver DF. Development of quantitative structure-activity relationships and classification models for anticonvulsant activity of hydantoin analogues. Journal of Chemical Information and Computer Sciences. 43: 1028-36. PMID 12767162 DOI: 10.1021/Ci025639W  0.491
2003 O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood. 102: 549-57. PMID 12649144 DOI: 10.1182/Blood-2002-12-3693  0.318
2003 Jones RS, Sutherland J, Weaver DF. Synthesis of 4-ethoxycarbonyl-5-arylisoxazolidines via regioselective cycloaddition Synthetic Communications. 33: 43-51. DOI: 10.1081/Scc-120015557  0.394
Show low-probability matches.